Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab sarotalocan + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Rakuten Medical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Topical Illumination (photoimmunotherapy For Cetuximab Sarotalocan; Near-infrared Light Applied Locally To Tumor Sites After Drug Infusion)
01
Overview
Cetuximab sarotalocan + pembrolizumab is a **combination therapy** for recurrent/locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC). Cetuximab sarotalocan is an antibody-drug conjugate consisting of cetuximab (an EGFR monoclonal antibody) conjugated to IRDye 700DX, administered intravenously and activated by near-infrared photoimmunotherapy (PIT). Pembrolizumab is a monoclonal antibody targeting PD-1, acting as an immune checkpoint inhibitor. The combination leverages direct tumor cell killing by PIT-induced cytotoxicity (cetuximab sarotalocan) and antitumor immunity via PD-1 blockade (pembrolizumab). Key indications are recurrent/metastatic or locally advanced HNSCC in patients with few treatment options. Rakuten Medical commercializes cetuximab sarotalocan (ASP-1929). Combination trials with pembrolizumab are ongoing, and preliminary results show promising clinical activity and tolerability[5][4].
- Brand names
- ASP-1929ASP1929ASP 1929
- Other names
- cetuximab sarotalocan sodiumASP-1929 PhotoimmunotherapyASP1929 PhotoimmunotherapyASP 1929 Photoimmunotherapycetuximab-IRDye 700DX conjugatecetuximab-IRDye700DX conjugatecetuximab-IRDye-700DX conjugate
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on cetuximab sarotalocan + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab sarotalocan + pembrolizumab.